Phase I/II proof of concept trial of dCellVax in patients with metastatic breast cancer
Phase of Trial: Phase I/II
Latest Information Update: 14 Sep 2016
Price : $35 *
At a glance
- Drugs IDO-silenced dendritic cell vaccine Regen BioPharma (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Regen BioPharma
- 14 Sep 2016 According to Regen BioPharma media release, the company has announced submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug (IND) application.
- 27 May 2015 According to a Regen BioPharma media release, the company is currently in the process of addressing FDA questions related to the submitted IND (IND #16200) before starting the clinical trial.
- 09 Apr 2013 New trial record